What is Danaher Corporation (DHR) DCF Fair Value and Intrinsic Value in 2026?

Danaher Corporation (DHR) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Danaher Corporation's historical Return on Invested Capital (ROIC) and Moat Rating?

Danaher Corporation operates in the Healthcare sector (Diagnostics & Research) with an economic moat rating of WIDE. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Danaher Corporation's financial health rating and Piotroski F-Score?

Danaher Corporation's balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Danaher Corporation (DHR) for quarterly SEC filing thesis breaks?

LocalAlpha audits Danaher Corporation's 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksDHR

DHR

Danaher CorporationHealthcare / Diagnostics & ResearchINTACT

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Share Price

$200.14

52W: $160.93 - $242.8

DCF Fair Value

$108.46

-84.5% Premium

Thesis Hub

P/E (TTM)

35.7x

ROIC

14.9%

Operating Margin

19.8%

FCF Yield

3.1%

Debt / Equity

0.53x

Piotroski Score

8/9

Altman Z-Score

3.13

Market Cap

$140.7B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($108.46)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$108.46

MOS Buy Target (-25%)

$81.34

Valuation Overlays: DCF Fair Value ($108.46) 25% MOS Buy Target ($81.34) Revised Graham ($120.33) Graham Number ($97.17)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$200.14

DCF Fair Value

$108.13

-85.1% Premium

Starting Free Cash Flow ($M)$4,325M

$100M$4,325M (Reported)$50,000M

Stage 1 Growth (Years 1-5)9.9%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$23,600M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$42.1B

PV of Terminal Value

$57.6B

Implied Enterprise Value

$99.6B

Implied Equity Value

$76.0B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$4,753	$5,224	$5,741	$6,309	$6,934	$7,246	$7,572	$7,913	$8,269	$8,641
Present Value (PV)	$4,361	$4,397	$4,433	$4,470	$4,507	$4,320	$4,142	$3,971	$3,807	$3,650

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-106% Premium

$97.17

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $5.61BVPS: $74.81

Revised Graham Formula-66.3% Premium

$120.33

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings2.9% Yield

$5.84 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $4.1BYield: 2.9%

Reverse DCF: Market Growth Expectation

FAIR BARRIER

12.1% CAGR (Next 10 Yrs)

At the current price of $200.14, the market is assuming the business will compound Free Cash Flow at 12.1% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

ℹ Fair expectations: Requires steady execution.

Autonomous Thesis Underwriting

Surveil DHR with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Danaher Corporation. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 19.8% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track DHR & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Danaher Corporation (DHR) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Danaher Corporation.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Danaher Corporation has an estimated DCF intrinsic fair value of $108.46 per share compared to its current market price of $200.14. This represents an estimated 84.5% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $97.17.